Albumin fusion proteins
First Claim
1. A method of treating memory loss in a patient, comprising administering to said patient an albumin fusion protein comprising two or more tandemly oriented glucagon-like peptide-1 (GLP-1) polypeptides, wherein (i) said GLP-1 polypeptides are selected from wild-type GLP-1, GLP-1 fragments, and GLP-1 variants, fused to albumin comprising the amino acid sequence of SEQ ID NO:
- 1, fragment or variant thereof, (ii) said albumin fusion protein has an increased serum plasma half-life compared with GLP-1 that is not fused to said albumin or a fragment or variant thereof, and (iii) said albumin fusion protein has GLP-1 activity.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
-
Citations
14 Claims
-
1. A method of treating memory loss in a patient, comprising administering to said patient an albumin fusion protein comprising two or more tandemly oriented glucagon-like peptide-1 (GLP-1) polypeptides, wherein (i) said GLP-1 polypeptides are selected from wild-type GLP-1, GLP-1 fragments, and GLP-1 variants, fused to albumin comprising the amino acid sequence of SEQ ID NO:
- 1, fragment or variant thereof, (ii) said albumin fusion protein has an increased serum plasma half-life compared with GLP-1 that is not fused to said albumin or a fragment or variant thereof, and (iii) said albumin fusion protein has GLP-1 activity.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9)
-
10. A method of treating memory loss in a patient, comprising administering to said patient an albumin fusion protein comprising a single copy of GLP-1(7-36(A8G)), fused to albumin comprising the amino acid sequence of SEQ ID NO:
- 1, fragment or variant thereof, (ii) said albumin fusion protein has an increased serum plasma half life compared with GLP-1 that is not fused to said albumin or a fragment or variant thereof, and (iii) said albumin fusion protein has GLP-1 activity.
- View Dependent Claims (11, 12, 13, 14)
Specification